"The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.
“Opdivo provides an"...
Sancuso Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Sancuso (Granisetron Transdermal System) skin patch is an anti-nauseant and antiemetic used to prevent nausea and vomiting caused by cancer chemotherapy. Common side effects of Sancuso include constipation, diarrhea, nausea, vomiting, stomach pain, loss of appetite, headache, itching or skin irritation where the patch is worn, dizziness, drowsiness, anxiety, sleep problems (insomnia), or temporary hair loss.
The dose of Sancuso is a single patch applied to the upper outer arm a minimum of 24 hours and a maximum of 48 hours before chemotherapy, and removed a minimum of 24 hours after chemotherapy completion. The patch can be worn up to 7 days depending on the duration of the chemotherapy. Sancuso may interact with other drugs. Tell your doctor all medications and supplements you use. Natural or artificial sunlight can cause a skin reaction where the skin patch is worn. Wear protective clothing over your arms while you are wearing the skin patch and for at least 10 days after you remove a patch. During pregnancy, Sancuso should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Sancuso (Granisetron Transdermal System) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Sancuso in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Remove the skin patch and call your doctor at once if you have a serious side effect such as:
- severe redness, itching, swelling, or other irritation where the patch is worn;
- uneven heart rate;
- fever, pale skin, easy bruising or bleeding; or
- feeling like you might pass out.
Less serious side effects may include:
- diarrhea, constipation;
- nausea, vomiting, stomach pain;
- loss of appetite;
- mild itching or skin irritation where the patch is worn;
- dizziness, drowsiness, anxiety;
- sleep problems (insomnia); or
- temporary hair loss.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Sancuso (Granisetron Transdermal System)
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Sancuso Overview - Patient Information: Side Effects
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor immediately if this unlikely but serious side effect occurs: stomach/abdominal pain or swelling.
This medication may increase serotonin and rarely cause a very serious condition called serotonin syndrome/toxicity. The risk increases if you are also taking other drugs that increase serotonin, so tell your doctor or pharmacist of all the drugs you take (see Drug Interactions section). Get medical help right away if you develop some of the following symptoms: fast heartbeat, hallucinations, loss of coordination, severe dizziness, severe nausea/vomiting/diarrhea, twitching muscles, unexplained fever, unusual agitation/restlessness.
A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Sancuso (Granisetron Transdermal System)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Sancuso FDA Prescribing Information: Side Effects
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Sancuso was evaluated in a total of 404 patients undergoing chemotherapy who participated in two double-blind, comparator studies with patch treatment durations of up to 7 days. The control groups included a total of 406 patients who received a daily dose of 2 mg oral granisetron, for 1 to 5 days.
Adverse reactions occurred in 8.7% (35/404) of patients receiving Sancuso and 7.1% (29/406) of patients receiving oral granisetron. The most common adverse reaction was constipation that occurred in 5.4% of patients in the Sancuso group and 3.0% of patients in the oral granisetron group.
Table 1 lists the adverse reactions that occurred in at least 3% of patients treated with Sancuso or oral granisetron.
Table 1: Incidence of Adverse Reactions in
Double-Blind, Active Comparator Controlled Studies in Cancer Patients Receiving
Chemotherapy (Events ≥ 3% in either group)
|Body System Preferred Term||Sancuso TDS N=404 (%)||Oral granisetron N=406 (%)|
|Nervous system disorders|
5-HT3 receptor antagonists, such as granisetron, may be associated with arrhythmias or ECG abnormalities. Three ECGs were performed on 588 patients in a randomized, parallel group, double-blind, double-dummy study: at baseline before treatment, the first day of chemotherapy, and 5 to 7 days after starting chemotherapy. QTcF prolongation greater than 450 milliseconds was seen in a total of 11 (1.9%) patients after receiving granisetron, 8 (2.7%) on oral granisetron, and 3 (1.1%) on the patch. No new QTcF prolongation greater than 480 milliseconds was observed in any patient in this study. No arrhythmias were detected in this study.
Adverse reactions reported in clinical trials with other formulations of granisetron include the following:
Gastrointestinal: abdominal pain, diarrhea, constipation, elevation of ALT and AST levels, nausea and vomiting
The following adverse reactions have been identified during post approval use of Sancuso. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for Sancuso (Granisetron Transdermal System)
Additional Sancuso Information
Sancuso - User Reviews
Sancuso User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.